Abstract
Bladder cancer is the 8th most common cancer with 74,000 new cases in the United States (Tan et al. in Cancer Treat Rev 47:22–31, 2016). Transurethral resection and intravesical treatments remain the main treatment modality. Up to 31–78% of cases recur, hightlighting the need for intensive treatment and surveillance protocols (Tan et al. in Cancer Treat Rev 47:22–31,2016). This makes bladder cancer one of the most expensive cancers to manage (Tan et al. in Cancer Treat Rev 47:22–31, 2016). This chapter covers the management of non muscle invasive bladder cancer .
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Apolo AB, Vogelzang NJ, Theodorescu D. New and promising strategies in the management of bladder cancer. Am Soc Clin Oncol Educ Book. 2015:105–12.
Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, Hernández V, Kaasinen E, Palou J, Rouprêt M, van Rhijn BW, Shariat SF, Soukup V, Sylvester RJ, Zigeuner R. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017;71(3):447–61.
Burger M, Oosterlinck W, Konety B, Chang S, Gudjonsson S, Pruthi R, Soloway M, Solsona E, Sved P, Babjuk M, Brausi MA, Cheng C, Comperat E, Dinney C, Otto W, Shah J, Thürof J, Witjes JA. International consultation on urologic disease-European association of urology consultation on bladder cancer 2012. ICUD-EAU International consultation on bladder cancer 2012: non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2013;63(1):36–44.
Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, Pruthi R, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: Aua/Suo guideline. J Urol. 2016;196(4):1021–9.
Lum BL, Torti FM. Adjuvant intravesicular pharmacotherapy for NMI bladder cancer. J Natl Cancer Inst. 1991;83(10):682–94.
Pignot G, Irani J, Bastide C, Ravery V. New concepts in management of NMIBC in 2010. Prog Urol. 2011;21(Suppl. 2):S34–7.
Power NE, Izawa J. Comparison of guidelines on non-muscle invasive bladder cancer (EAU, CUA, AUA, NCCN, NICE). Bladder Cancer. 2016;2(1):27–36.
Rodriguez Faba O, Gaya JM, López JM, Capell M, De Gracia-Nieto AE, Gómez Correa E, Breda A, Palou J. Current management of non-muscle-invasive bladder cancer. Minerva Med. 2013;104(3):273–86.
Tan WS, Rodney S, Lamb B, Feneley M, Kelly J. Management of non-muscle invasive bladder cancer: a comprehensive analysis of guidelines from the United States, Europe and Asia. Cancer Treat Rev. 2016;47:22–31.
Wallerand H. Management of non invasive bladder tumours (NMIBC). Bull Cancer. 2010;97(Suppl. Cancer de la vessie):11–7.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Goonewardene, S.S., Persad, R., Motiwala, H., Albala, D. (2020). Management of Non-Muscle Invasive Bladder Cancer. In: Management of Non-Muscle Invasive Bladder Cancer. Springer, Cham. https://doi.org/10.1007/978-3-030-28646-0_18
Download citation
DOI: https://doi.org/10.1007/978-3-030-28646-0_18
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-28645-3
Online ISBN: 978-3-030-28646-0
eBook Packages: MedicineMedicine (R0)